Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Gynecologic 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Neoplasms 1Kidney Neoplasms 1Esophageal Neoplasms 1

Interventions

Gemcitabine 677130-nm albumin-bound paclitaxel 197Fluorouracil 184Oxaliplatin 173Albumin-Bound Paclitaxel 151Capecitabine 137Leucovorin 129Irinotecan 111Radiotherapy 95Taxes 83pembrolizumab 80Cisplatin 71Erlotinib Hydrochloride 69Radiosurgery 67Nivolumab 56Bevacizumab 54Drug Therapy 52Cyclophosphamide 48Magnetic Resonance Spectroscopy 45folfirinox 42Docetaxel 41Cetuximab 40irinotecan sucrosofate 36Specimen Handling 36S 1 (combination) 36Biopsy 30Radiation 29Paclitaxel 29Ipilimumab 27Surgical Procedures, Operative 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Pancreatic Neoplasms × Histocompatibility Testing × Clear all
NCT06144762 2025-02-12

PANC-O-MICS

Institut du Cancer de Montpellier - Val d'Aurelle

Phase NA Recruiting
150 enrolled
GastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms

NCT01434550 2017-02-23

Phase II Study of First-line SBRT in Patients With Non-Metastatic Unresectable Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡